Skip to market wire
InvestLog
Back to Market返回行情

ADIA Adia Med Inc.

OTCHealthcare
$0.1100-8.33%ClosedMarket Cap: $10.4M

As of 2026-08-21 16:00

Why ADIA matters now

Adia Med Inc. (ADIA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.11 with -8.33% on the session and $10.4M in market capitalization.

The latest indexable market news headline is "Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting" from Newsfile Corp.

Latest News

Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ UplistingNewsfile Corp · 2026-08-24
Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First HalfNewsfile Corp · 2026-08-13
Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and MarketingNewsfile Corp · 2026-08-11
Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration OpportunitiesNewsfile Corp · 2026-08-05
Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical StudyNewsfile Corp · 2026-07-29

Company Info

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

US

Exchange

OTC

Beta

-8.23

Adia Med Inc. is a publicly traded company dedicated to advancing regenerative medicine and healthcare innovation. The company operates through its primary divisions: Adia Med clinics and Adia Labs LLC. Adia Med clinics deliver specialized regenerative treatments, including stem cell therapies, while Adia Labs manufactures and distributes regenerative products. The company is also involved in multiple Institutional Review Board (IRB)-approved clinical studies.